Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AUT00206 in healthy volunteers
NCT02589262Phase 1Completed
- Sponsor
- Autifony Therapeutics
- Start
- Sep 2015
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AUT00206 in schizophrenia (4 arms), sponsored by Autifony Therapeutics. Primary endpoint: Number of treatment emergent adverse events up to 14 weeks. Started Sep 2015; status: completed.
02
Drugs
AUT00206
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT02589262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02589262.